{
    "nctId": "NCT00471432",
    "briefTitle": "OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors",
    "officialTitle": "A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel",
    "overallStatus": "COMPLETED",
    "conditions": "Bladder Cancer, Breast Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Dose-limiting toxicity",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed solid tumors that have been shown to overexpress clusterin, including but not limited to, any of the following:\n\n  * Prostate cancer\n  * Renal cell carcinoma\n  * Non-small cell lung cancer\n  * Bladder cancer\n  * Breast cancer\n  * Ovarian cancer\n* Metastatic or locally recurrent disease\n* Refractory to standard curative therapy or no standard curative therapy exists\n\n  * Patients with prostate cancer must be hormone refractory (i.e., have documented evidence of progression while receiving androgen ablative therapy)\n* Measurable or nonmeasurable disease\n\n  * Measurable disease defined as measurable lesion \u2265 20 mm by x-ray, physical exam, or nonspiral CT scan or \u2265 10 mm by spiral CT scan\n* No documented CNS metastases\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Life expectancy \u2265 12 weeks\n* Absolute granulocyte count \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Bilirubin normal\n* Creatinine \u2264 2 times upper limit of normal (ULN)\n* AST and ALT \u2264 1.5 times ULN\n* PT/INR and PTT normal\n* No uncontrolled pain\n* No known bleeding disorder\n* No history of serious allergic reaction to taxane (paclitaxel or docetaxel)\n* No preexisting peripheral neuropathy \u2265 grade 2\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No other serious illness or medical conditions that would preclude study compliance, including any of the following:\n\n  * Active uncontrolled infection\n  * Significant cardiac dysfunction\n* No significant neurological disorder that would preclude giving informed consent\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior strontium chloride Sr 89\n* No more than 2 prior chemotherapy regimens, including adjuvant or neoadjuvant chemotherapy (for patients assigned to schedule B \\[docetaxel once every 3 weeks\\])\n* More than 4 weeks since prior chemotherapy and recovered\n* At least 4 weeks since prior antiandrogens\n* More than 4 weeks since prior external-beam radiotherapy, except low-dose nonmyelosuppressive radiotherapy\n* No prior radiotherapy to \u2265 30% of marrow-bearing areas (for patients assigned to schedule B \\[docetaxel once every 3 weeks\\])\n* At least 28 days since prior new anticancer therapy\n* At least 28 days since prior and no other concurrent investigational agents\n* No concurrent radiotherapy, except low-dose nonmyelosuppressive radiotherapy\n* No other concurrent cytotoxic therapy\n* Concurrent luteinizing hormone-releasing hormone agonist allowed (if already initiated in patients with prostate cancer)\n* No concurrent anticoagulant therapy (i.e., heparin, warfarin)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}